Brief: GBS Inc. Announces Plans For Clinical Sars-Cov-2 Antibody Trials Following Validation Study
30/11/2021 13:57
Nov 30 (Reuters) - Gbs Inc GBS.O :
* GBS INC. ANNOUNCES PLANS FOR CLINICAL SARS-COV-2 ANTIBODY
TRIALS
FOLLOWING VALIDATION STUDY
Source text for Eikon: ID:nGNX2L2H0J
Further company coverage: GBS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelligent Bio Solutions
See all newsBrief: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth
Brief: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance And Planned US Market Entry
Intelligent Bio Solutions Q3 revenue rises 46%, gross margin tops 50%
Intelligent Bio Solutions rise after clearing security tests ahead of FDA filing
Brief: Intelligent Bio Solutions Completes Clinical Cut-Off Study